Navigation Links
Unraveling biological networks
Date:3/5/2012

nd clusters them hierarchically to reveal the presence of recurring motifs in the network. The team has applied the algorithm to a network of protein-protein interaction (PPI) for the well-studied bacterium Escherichia coli and the yeast Saccharomyces cerevisiae.

"Our experimental results show that the algorithm can efficiently discover motifs, which are consistent with current biology knowledge," the team says. Importantly, however, the approach has also revealed several novel motifs previously unrecognised. "Our algorithm can detect several consensus motifs with a given size, which may help biologists go further into cellular process," the team adds.


'/>"/>

Contact: Lin Gao
lgao@mail.xidian.edu.cn
Inderscience Publishers
Source:Eurekalert

Page: 1 2

Related biology news :

1. Brain structure provides key to unraveling function of bizarre dinosaur crests
2. Physics, math provide clues to unraveling cancer
3. March of Dimes awards $250,000 prize to scientists unraveling the causes of muscular dystrophy
4. New book offers practical advice for unraveling the genetics of complex human diseases
5. Tel Aviv University President Co-authors Important Paper Unraveling the Effect of Spatial Organization on Intracellular Chemistry
6. Unraveling Alzheimers: Simple small molecules could untangle complex disease
7. Unraveling a new regulator of cystic fibrosis
8. Unraveling Batten disease
9. Biological sand filters, a practical approach to combat poverty and inequality
10. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
11. GEN reports on novel tools for deciphering biological networks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DENVER , Oct. 20, 2014  Leading identity ... years time half of the world,s population will have ... in Europe . Asia ... dominate the market accounting for more than 60% of ... Acuity,s report  -- "The Global National ...
(Date:10/18/2014)... patients with undiagnosed, suspected genetic conditions, a certain type ... molecular diagnostic yield than traditional molecular diagnostic methods, according ... study is being released to coincide with the American ... which sequences the protein­coding region of the genome (the ... a cell or organism), has been rapidly applied in ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2
... Langone Medical Center,s Departments of Orthopaedic Surgery and Radiology ... detect subtle changes in joint cartilage microstructure and ... of early osteoarthritis (OA). By using these techniques during ... the management of the disease from eventual joint reconstruction ...
... Texas A&M Institute of Renewable Natural Resources have discovered fresh ... in Texas, according to a research associate with the institute. ... single individual of false spike "Quadrula mitchelli" with tissue still ... recently alive in the San Saba River ...
... SAN FRANCISCO, CAAugust 14, 2011Scientists at the Gladstone Institutes ... proteins that, when out of balance, can prevent the normal ... be important in some types of cancer. "The news, ... Nature Cell Biology , adds to the understanding of the ...
Cached Biology News:NYU Langone experts find MRI techniques can detect early osteoarthritis 2Researchers discover freshwater mussel species thought to be extinct 2Researchers discover freshwater mussel species thought to be extinct 3Researchers discover freshwater mussel species thought to be extinct 4Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 2Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 3
(Date:10/22/2014)... YORK , Oct. 22, 2014 New ... in the in vitro diagnostic (IVD) test industry, especially ... Information. The healthcare market researcher listed more than 25 testing ... could be the future of IVD products. Kalorama details the ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... October 21, 2014 The North American ... market North America with analysis and forecast of revenue. ... and is expected to reach $623.6 million by 2018, ... , Browse through the TOC of the North American ... the in-depth analysis provided. This also provides a glimpse ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... 22 Insmed Inc. (Nasdaq:,INSM), a developer of follow-on ... the recently disclosed temporary suspension,of NASDAQ,s minimum bid closing ... the Company now has until March 20, 2009 to ... a closing bid price of $1.00 or more for ...
... NicOx,S.A. (Euronext Paris: COX) today reported financial results for the nine,months ... quarter of 2008:, - Positive top-line results from the 302 ... co-primary efficacy endpoints at week-13 (p naproxcinod 750 ... non-inferiority to naproxen 500 mg bid at week-13 and 26. ...
... to Show Encouraging and Durable Anti-Tumor Activity and ... Dose Escalation Continues -, - Results Presented at ... Targets and ... MDVN ) today announced the presentation of new data from an,ongoing Phase ...
Cached Biology Technology:NASDAQ's Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmed's Compliance Date to March 20, 2009 2NicOx Reports Results for the First Three Quarters of 2008 2NicOx Reports Results for the First Three Quarters of 2008 3NicOx Reports Results for the First Three Quarters of 2008 4NicOx Reports Results for the First Three Quarters of 2008 5NicOx Reports Results for the First Three Quarters of 2008 6NicOx Reports Results for the First Three Quarters of 2008 7NicOx Reports Results for the First Three Quarters of 2008 8NicOx Reports Results for the First Three Quarters of 2008 9NicOx Reports Results for the First Three Quarters of 2008 10Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4